

For Immediate Release
Alembic Pharmaceuticals Limited
Consolidated Results for Quarter ended 31.12.2014

Editors Synopsis

- **Net sales up by 6% to Rs 514.9 crores against Rs 486.7 crores in the corresponding quarter last year**
- **Net profit after tax up by 7.2% to Rs 70.7 crores against Rs 65.9 crores in the corresponding quarter last year**
- **EBITDA margins is 19.9% at Rs 102.5 crores against 21% at Rs 102.2 crores in the corresponding quarter last year**
- **Net sales up by 11.2% for YTD DEC 14 to Rs 1559.8 crores against Rs 1403.2 crores in the corresponding period last year**
- **Net profit after tax up by 22% for YTD DEC 14 to Rs 212.6 crores against Rs 174.2 crores in the corresponding period last year**
- **EBITDA margins is 19.7% at Rs 307.4 crores for YTD DEC 14 against 19.0% at Rs 266.4 crores in the corresponding period last year**

Vadodara, 4th February, 2015

Alembic Pharmaceuticals Limited reported a 6% increase in revenues to Rs 514.9 crores for the quarter ended 31st December 2014, compared to Rs 486.7 crores in the corresponding quarter last year.

The net profit grew by 7.2% at Rs 70.7 crores for the quarter ended 31st December 2014 against Rs 65.9 crores in corresponding quarter last fiscal.

EBITDA margins for quarter ended 31st December 2014 is 19.9% at Rs 102.5 crores against 21% at Rs 102.2 crores in the corresponding quarter last year.

The company reported 11.2% increase in revenue for YTD DEC 14 to Rs 1559.8 crores against Rs 1403.2 crores corresponding period last year.

The Company also reported 22% growth in net profit for YTD DEC 14 at Rs 212.6 crores against Rs 174.2 crores in corresponding period last year.

India Branded Formulations Business

The India Branded formulations business posted sales of Rs 250.0 crores against Rs 225.1 crores with a 11% growth over the corresponding quarter of the previous year.

Specialty and Acute segments grew by 19% and 3% respectively in current quarter.

International Generics

International Generic Formulation posted growth of 3% and posted sales of Rs 133.3 crores against Rs 129.6 crores over the corresponding quarter last year.

1 ANDA application was filed during the quarter, 5 ANDA applications for the YTD DEC 14, taking cumulative ANDA filings of the Company to 66. During the quarter 1 ANDA approval was received, 4 ANDA approvals for the YTD DEC 14, taking cumulative ANDA/NDA approvals to 36 (including 4 tentative approvals).

2 DMF applications were filed during the quarter, 4 DMF applications for the YTD DEC 14, taking cumulative DMF filings of the Company to 70.

Summary of Total Revenue is as under:

(Rs in Lacs)

| Particulars | Q3 FY15 | Q3 FY14 | % Change | YTD DEC FY15 | YTD DEC FY14 | % Change |
|--------------------------|--------------|--------------|-----------|---------------|---------------|------------|
| Formulation | | | | | | |
| India Branded | 24997 | 22505 | 11% | 74876 | 65111 | 15% |
| India Generics | 3321 | 2886 | 15% | 9065 | 9212 | (-)2% |
| International Branded | 1343 | 2269 | (-)41% | 5447 | 5601 | (-)3% |
| International Generics | 13333 | 12962 | 3% | 37058 | 32876 | 13% |
| API | 8131 | 7564 | 7% | 28126 | 26081 | 8% |
| Export Incentives | 365 | 488 | - | 1406 | 1438 | - |
| Total | 51490 | 48674 | 6% | 155978 | 140319 | 11% |

The Profit break-up is as under:

(Rs in Lacs)

| Particulars | Q3 FY15 | Q3 FY14 | % Change | YTD DEC FY15 | YTD DEC FY14 | % Change |
|----------------------|------------|------------|-------------|--------------------|--------------------|-------------|
| EBITDA | 10248 | 10223 | 0.2% | 30741 | 26642 | 15.4% |
| Profit Before Tax | 8998 | 8883 | 1.3% | 27060 | 22982 | 17.7% |
| Net Profit after Tax | 7066 | 6593 | 7.2% | 21260 | 17421 | 22.0% |

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 4500 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

| | |
|---|---|
| Ajay Kumar Desai Phone: +91 22 – 306 11681 Email: ajay.desai@alembic.co.in | Mitanshu Shah Phone: +91 265 – 3007630 Email: mitanshu.shah@alembic.co.in |
|---|---|